Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 2.4 to 1.9.
Financials
Financial year 2025
PHARMACIE P. LEROY from Engis, company number BE0433775882, closed financial year 2025 with a result of € 64,620 after tax. For that financial year PHARMACIE P. LEROY recorded a gross margin of € 375,959 and equity of € 499,265. Compared with financial year 2024, the result moved from € 91,297 to € 64,620. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ 499,265
▼ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 64,620
▼ 29% vs 2024
Profit after tax over the fiscal year.
€ 193,962
▲ 2% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 107,100 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
1.9
▼ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 151,761
▲ 6% vs 2024
€ 79,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,580
▼ 28% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 329,562
▼ 17% vs 2024
€ 88,239 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 80,640
▼ 30% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 48,243
▲ 110% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 386,241 | € 413,208 | € 401,452 | € 375,959 | ▼ 6% |
| Profit after taxes | € 88,332 | € 124,994 | € 91,297 | € 64,620 | ▼ 29% |
| Equity | € 539,653 | € 557,547 | € 541,745 | € 499,265 | ▼ 8% |
| Total debts | € 655,781 | € 607,678 | € 616,673 | € 593,537 | ▼ 4% |
| Cash | € 182,082 | € 188,995 | € 190,073 | € 193,962 | ▲ 2% |
| Land & buildings | € 613,207 | € 552,898 | € 499,849 | € 447,137 | ▼ 11% |
| Retained profit | € 477,653 | € 495,547 | € 479,745 | € 437,265 | ▼ 9% |
| Dividend | € 107,100 | € 107,100 | € 107,100 | € 107,100 | |
| Bank debt | € 555,507 | € 477,150 | € 398,471 | € 329,562 | ▼ 17% |
| Balance sheet total | € 1,195,434 | € 1,165,225 | € 1,158,417 | € 1,092,802 | ▼ 6% |
| Employees (FTE) | 2.3 | 2.4 | 2.2 | 1.9 | ▼ 0.3 |
By gross margin, PHARMACIE P. LEROY ranks 73rd of 348 companies with main activity “Detailhandel in farmaceutische producten” in the province of Liège that publish figures (fiscal year 2025).
Key figures of PHARMACIE P. LEROY, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about PHARMACIE P. LEROY the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to PHARMACIE P. LEROY?
What happened at PHARMACIE P. LEROY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- LEROY - Invest & C° stepped down as director. NBB
- Abigaël HULIN stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 64,620 (▼ 29% vs 2024). filed late Source: NBB ↗
- LEROY - Invest & C° became a director. NBB
- Abigaël HULIN became a director. NBB
- New establishment in Engis. KBO
- Start of the company according to the CBE. KBO
In short
From € 88,332 profit in 2022 to € 64,620 profit in 2025.
Paid € 143,056 in corporate taxes since 2022.
Best year ever: 2023, with € 124,994 profit.
On average € 197,900 of value added per employee in 2025.
Management
The stake of LEROY - Invest & C° comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMACIE P. LEROYThe shares are held by LEROY - Invest & C° (96%).
Directors
According to the 2025 annual accounts
Managing director · represented by Grégory LEROY
since 2023 · until 2029
Abigaël HULIN
Director
since 2023 · until 2029
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue de la Station(ENG) 15
4480 Engis
Quai Léopold Herten(ENG) 14 box c
4480 Engis
Active since 18 December 2001
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in the province of Liège
Same main activity (Detailhandel in farmaceutische producten), 392 active companies in the province of Liège, largest first.
PHARMACIES POPULAIRES DE VERVIERS ET ARRONDISSEMENT
€ 109.5 million revenue · 2025 · Thimister-Clermont
LES PHARMACIES DU PEUPLE - Réseau Solidaris
€ 44.8 million revenue · 2025 · Seraing
€ 19.4 million revenue · 2025 · Bütgenbach
€ 17.9 million revenue · 2025 · Thimister-Clermont
Pharmacie populaire La Sauvegarde
€ 17.8 million revenue · 2025 · Soumagne
€ 12.4 million revenue · 2025 · Faimes
Details
- Company number
- 0433.775.882
- VAT number
- BE 0433.775.882
- Registered office
- Rue de la Station(ENG) 15, 4480 Engis
- Names & denominations
- PHARMACIE P. LEROY
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 March 1988
- Peppol
- Active · Active since 13 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers